


**KILITCH DRUGS (INDIA) LIMITED**  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2013**  
 Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Rs. in Lacs

PART I Sr. No.	Particulars	Three Months Ended			Nine Months Ended		Year ended
		31-12-2013	30-09-2013	31-12-2012	31-12-2013	31-12-2012	31-03-2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from operations</b>						
	(a) Net Sales/Income from operations (net of Excise)	131.16	288.10	344.88	787.92	2415.75	3199.01
	(b) Other operating income	21.62	66.99	0.00	88.61	0.00	119.07
	<b>Total income from Operations (Net)</b>	<b>152.79</b>	<b>355.09</b>	<b>344.88</b>	<b>876.54</b>	<b>2415.75</b>	<b>3318.08</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	98.21	32.55	157.91	368.43	1955.49	2659.83
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(173.32)	45.65	23.39	(171.72)	24.45	26.13
	(c) Employee Benefit Expenses	71.45	63.43	106.72	195.68	226.15	303.45
	(d) Depreciation and Amortisation Expenses	33.17	32.78	32.83	99.03	98.45	122.90
	(e) Other Expenses	171.53	198.14	167.77	479.19	508.59	695.89
	<b>Total Expenses</b>	<b>201.04</b>	<b>372.55</b>	<b>488.62</b>	<b>970.62</b>	<b>2813.14</b>	<b>3808.20</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(48.25)</b>	<b>(17.46)</b>	<b>(143.74)</b>	<b>(94.08)</b>	<b>(397.39)</b>	<b>(490.12)</b>
4	Other Income	144.18	99.55	207.19	454.25	791.60	915.05
5	<b>Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>95.93</b>	<b>82.09</b>	<b>63.45</b>	<b>360.17</b>	<b>394.21</b>	<b>424.93</b>
6	Finance Costs	0.00	(6.18)	0.00	0.00	7.16	1.91
7	<b>Profit / (Loss) from ordinary activities before exceptional items (5-6)</b>	<b>95.93</b>	<b>88.27</b>	<b>63.45</b>	<b>360.17</b>	<b>387.05</b>	<b>423.02</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from ordinary activities before tax (7+8)</b>	<b>95.93</b>	<b>88.27</b>	<b>63.45</b>	<b>360.17</b>	<b>387.05</b>	<b>423.02</b>
10	Tax Expenses						
	Current Tax	14.70	45.30	0.00	60.00		0.00
	Deferred Tax	0.40	(2.41)	0.00	(2.01)	2.00	(0.71)
11	<b>Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>80.83</b>	<b>45.38</b>	<b>63.45</b>	<b>302.18</b>	<b>385.05</b>	<b>423.73</b>
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	95.46
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>80.83</b>	<b>45.38</b>	<b>63.45</b>	<b>302.18</b>	<b>385.05</b>	<b>328.27</b>
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]						10582.00
16.	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	0.61	0.34	0.48	2.28	2.91	3.20
	(b) Diluted	0.61	0.34	0.44	2.28	2.65	3.15
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	0.61	0.34	0.48	2.28	2.91	2.48
	(b) Diluted	0.61	0.34	0.44	2.28	2.65	2.44



PART II		31-12-2013	30-09-2013	31-12-2012	31-12-2013	31-12-2012	31-03-2013
<b>A PARTICULARS OF SHAREHOLDING</b>							
1	Public shareholding	4697655	4697655	4706393	4697655	4706393	4706393
	a) Number of shares	35.50	35.50	35.57	35.50	35.57	35.57
	b) Percentage of shareholding						
2	Promoters and Promoter Group Shareholding **						
	a) Pledge / Encumbered						
	Number of shares						
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)						
	Percentage of shares (as a % of the total share capital of the company)						
	b) Non-encumbered						
	Number of shares	8534173	8534173	8525435	8534173	8525435	8525435
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	64.50	64.50	64.43	64.50	64.43	64.43

<b>B INVESTOR COMPLAINTS</b>		
Pending at the beginning of the Quarter		NIL
Received during the quarter		10
Disposed off during the quarter		10
Remaining unresolved at the end of the quarter		NIL

- Notes:**
- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 13th February, 2014.
  - During the quarter, the company has operated only in one segment i.e. Pharmaceuticals.
  - The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.
  - The Auditors of the Company have Reviewed the Financial Results for the quarter ended 31st December, 2013 in accordance with clause 41 of listing agreement with the stock exchanges.



For and on Behalf of the Board  
*Bhavin Mukund Mehta*  
 BHAVIN MUKUND MEHTA  
 (Director)



Place: Mumbai  
 Date: 13th February, 2014

**A.M.GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

AJIT M. GHELANI  
 B.Com.(Hons), F.C.A, GRAD.C.W.A.


CHINTAN A. GHELANI  
 B.Com.(Hons), F.C.A, C.S.


To,  
 The Board of Directors,  
 KILITCH DRUGS (INDIA) LIMITED

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF  
 KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 31.12.2013**

1. We have reviewed the accompanying statement of unaudited standalone financial results of M/s. Kilitch Drugs (India) Limited for the quarter ended 31<sup>st</sup> December, 2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company  
 Chartered Accountants  
 (Firm Registration No. 103173W)

  
 Chintan A. Ghelani  
 Partner  
 Membership No. 104391



Place: Mumbai  
 Date: 13-02-2014

Enclosed: Unaudited financial results for the quarter ended 31<sup>st</sup> December, 2013 of  
 M/s. Kilitch Drugs (India) Limited.